Aghi M - Search Results

1

Prodrug activation enzymes in cancer gene therapy.

Aghi M, Hochberg F, Breakefield XO. Aghi M, et al. J Gene Med. 2000 May-Jun;2(3):148-64. doi: 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO;2-Q. J Gene Med. 2000. PMID: 10894261 Review.

2

Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.

Kramm CM, Chase M, Herrlinger U, Jacobs A, Pechan PA, Rainov NG, Sena-Esteves M, Aghi M, Barnett FH, Chiocca EA, Breakefield XO. Kramm CM, et al. Among authors: aghi m. Hum Gene Ther. 1997 Nov 20;8(17):2057-68. doi: 10.1089/hum.1997.8.17-2057. Hum Gene Ther. 1997. PMID: 9414254

3

Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies.

Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Aghi M, et al. J Natl Cancer Inst. 1998 Mar 4;90(5):370-80. doi: 10.1093/jnci/90.5.370. J Natl Cancer Inst. 1998. PMID: 9498487

4

Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo.

Aghi M, Kramm CM, Breakefield XO. Aghi M, et al. J Natl Cancer Inst. 1999 Jul 21;91(14):1233-41. doi: 10.1093/jnci/91.14.1233. J Natl Cancer Inst. 1999. PMID: 10413425

5

Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies.

Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA. Aghi M, et al. Cancer Res. 1999 Aug 15;59(16):3861-5. Cancer Res. 1999. PMID: 10463570

6

RESPONSE: Re: Folylpolyglutamyl Synthetase Gene Transfer and Glioma Antifolate Sensitivity in Culture and In Vivo.

Aghi M, Kramm CM, Breakefield XO. Aghi M, et al. J Natl Cancer Inst. 1999 Dec 1;91(23):2048-2049. doi: 10.1093/jnci/91.23.2048. J Natl Cancer Inst. 1999. PMID: 10580034 No abstract available.

7

Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.

Pechan PA, Herrlinger U, Aghi M, Jacobs A, Breakefield XO. Pechan PA, et al. Among authors: aghi m. J Gene Med. 1999 May-Jun;1(3):176-85. doi: 10.1002/(SICI)1521-2254(199905/06)1:3<176::AID-JGM35>3.0.CO;2-T. J Gene Med. 1999. PMID: 10738566

8

Viral therapy for glioblastoma.

Chiocca EA, Aghi M, Fulci G. Chiocca EA, et al. Among authors: aghi m. Cancer J. 2003 May-Jun;9(3):167-79. doi: 10.1097/00130404-200305000-00005. Cancer J. 2003. PMID: 12952302 Review.

9

Gene therapy for glioblastoma.

Aghi M, Chiocca EA. Aghi M, et al. Neurosurg Focus. 2006 Apr 15;20(4):E18. Neurosurg Focus. 2006. PMID: 16709023 Review.

10

HSV-1 Vectors for Gene Therapy of Experimental CNS Tumors.

Herrlinger U, Jacobs A, Aghi M, Schuback DE, Breakefield XO. Herrlinger U, et al. Among authors: aghi m. Methods Mol Med. 2000;35:287-312. doi: 10.1385/1-59259-086-1:287. Methods Mol Med. 2000. PMID: 21390812

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

347 results

Search Page